Price Target Adjustment#
BofA Securities has decreased its price target for BioNTech (NASDAQ:BNTX) from $130 to $125, while still maintaining a Buy rating on the stock. This change follows the company's first-quarter revenue report, which showed earnings of €118 million, falling short of the consensus estimate of €171 million.
Financial Performance#
The reported revenue was also below BofA's own projection of €109 million for the quarter. Currently, BioNTech's stock trades at $95.96, with a market capitalization of $24.3 billion. Over the past twelve months, the company has not been profitable, reporting an earnings per share (EPS) of -$5.52, indicating a loss per share.
Ongoing Developments#
Despite the revenue miss, BioNTech is actively pursuing growth in its oncology division. The company has initiated five new pivotal trials for its drug pumitamig and continues to expand its combination therapy strategy. BioNTech has reaffirmed its revenue guidance for fiscal 2026, projecting between €2 billion and €2.3 billion, which includes about €613 million from its collaboration with Bristol Myers Squibb.
Analyst Sentiment#
BofA Securities is optimistic about the commercial potential of pumitamig and expects several clinical trial results this year. Other analysts have varied opinions; while H.C. Wainwright maintains a Buy rating with a price target of $130, Leerink Partners has lowered its target to $94, citing concerns about BioNTech's next-generation treatments. These mixed assessments reflect a cautious yet hopeful outlook on BioNTech's future prospects as it navigates ongoing clinical trials and leadership changes.